Hookipa Pharma (HOOK) AI Stock Analysis

• Market Cap: $11.34M
• Dividend Yield: N/A
• Average Volume (3M): 79.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.24
• Revenue Growth: -82.54%
• EPS Growth: -12.53%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,930,789
• 10 Day Avg. Volume: 17,921
• 30 Day Avg. Volume: 79,853
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -2.31
• Enterprise Value/Revenue: -2.81
• Enterprise Value/Gross Profit: -2.81
• Enterprise Value/Ebitda: 0.37
• 1Y Price Target: $1.00
• Price Target Upside: 7.53% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: $1.00 ▲(7.53% Upside)

Hookipa Pharma's overall stock score is low due to severe financial difficulties, negative technical indicators, and poor valuation metrics. The company's strategic decisions to sell assets and liquidate further exacerbate the risk, making it a highly speculative investment.

Positive Factors

Strategic Partnerships

Strategic partnerships provide a recurring revenue stream through upfront and milestone payments, supporting financial stability and growth.

Innovative Immunotherapy Focus

Focus on innovative immunotherapies positions the company in high-growth markets, leveraging proprietary technology for competitive advantage.

Low Leverage Risk

Minimal debt levels reduce financial risk, providing flexibility in financial management and resilience against economic downturns.

Negative Factors

Asset Sale and Liquidation

Asset sale and liquidation plans indicate a winding down of operations, posing a significant risk to the company's future viability and investor returns.

Zero Revenue in 2024

Lack of revenue generation and negative margins highlight severe financial challenges, threatening long-term sustainability and necessitating strategic shifts.

Negative Cash Flow

Persistent negative cash flow indicates operational inefficiency and the need for external capital, impacting the company's ability to sustain operations.

Hookipa Pharma Business Overview & Revenue Model

Company Description

Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative immunotherapies for the treatment of cancer and infectious diseases. Leveraging its proprietary technology platforms, Hookipa is engaged in creating novel therapies that harness the body's immune system to target and eliminate tumors or viral infections. The company's core product candidates include a range of immunotherapies designed to activate T cells and enhance immune responses.

How the Company Makes Money

Hookipa Pharma generates revenue primarily through strategic partnerships, collaborations, and potential licensing agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on development progress, and royalties on future sales of products developed in collaboration. Additionally, the company may receive funding through grants or government support aimed at advancing its clinical trials. As Hookipa progresses through clinical stages and achieves regulatory milestones, it can unlock significant financial resources from its partners, contributing to its overall revenue stream.

Hookipa Pharma Financial Statement Overview

Summary

Hookipa Pharma is facing significant financial difficulties, with zero revenue and persistent losses. The balance sheet shows low leverage risk but also declining equity value. Cash flow analysis reveals ongoing cash constraints, posing a risk to operations without new capital infusions.

Income Statement

Hookipa Pharma's income statement reveals a challenging financial performance with zero revenue in 2024, a significant decline from previous years. The gross profit margin is non-existent, and they have substantial negative EBIT and EBITDA margins. The net profit margin is also negative, reflecting ongoing losses. Revenue growth has been inconsistent, with a notable drop in the most recent year. The company's trajectory indicates financial instability and a need for strategic adjustments to improve revenue streams.

Balance Sheet

The balance sheet of Hookipa Pharma shows a moderate level of financial stability. The debt-to-equity ratio is low due to minimal debt, indicating low leverage risk. However, the return on equity is negative, driven by consecutive net losses. The equity ratio is satisfactory, suggesting a capital structure with a higher proportion of equity funding. Despite the low debt levels, the declining equity value and recurring losses raise concerns about long-term solvency and the need for improved operational performance.

Cash Flow

Cash flow analysis highlights significant challenges, with negative operating and free cash flows in 2024, further deteriorating from the previous year. The free cash flow to net income ratio and operating cash flow to net income ratio are adverse, reflecting cash outflows exceeding earnings. The free cash flow growth rate is negative, indicating a need for better cash management and operational efficiency. Overall, cash flow constraints pose a risk to sustaining operations without fresh capital infusions.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.35M	43.95M	20.13M	14.25M	18.45M	19.58M
Gross Profit	9.35M	41.19M	16.58M	10.65M	13.81M	-33.55M
EBITDA	-70.92M	-40.85M	-77.34M	-60.40M	-70.13M	-39.15M
Net Income	-73.31M	-43.50M	-81.58M	-64.92M	-75.67M	-44.08M
Balance Sheet
Total Assets	61.26M	82.55M	161.34M	170.45M	126.05M	187.82M
Cash, Cash Equivalents and Short-Term Investments	40.28M	39.68M	117.10M	113.44M	65.92M	143.18M
Total Debt	596.00K	875.00K	6.56M	6.50M	10.63M	10.51M
Total Liabilities	27.18M	31.33M	71.48M	67.94M	36.45M	31.69M
Stockholders Equity	34.08M	51.21M	89.86M	102.52M	89.59M	156.12M
Cash Flow
Free Cash Flow	-52.87M	-77.17M	-61.68M	-25.01M	-78.60M	-41.71M
Operating Cash Flow	-52.77M	-76.98M	-57.52M	-20.00M	-66.02M	-39.34M
Investing Cash Flow	-98.00K	-194.00K	-4.16M	-5.02M	-12.58M	-2.37M
Financing Cash Flow	-1.14M	-1.28M	65.67M	72.27M	-235.00K	73.42M

Hookipa Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOOK, the sentiment is Neutral. The current price of 0.93 is above the 20-day moving average (MA) of 0.90, below the 50-day MA of 0.96, and below the 200-day MA of 1.42, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.31 is Neutral, neither overbought nor oversold. The STOCH value of 51.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HOOK.

Hookipa Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
PHGE	44 Neutral	$12.29M	―	-99.35%	―	―	80.30%
PHIO	42 Neutral	$13.29M	―	-102.18%	―	―	85.26%
HOOK	40 Underperform	$11.34M	―	-105.79%	―	-82.54%	-12.53%
KZIA	31 Underperform	$9.11M	―	-3028.18%	―	―	-32.63%
WINT	28 Underperform	$1.82M	―	-169.59%	―	―	85.35%
PLRZ	―	$5.85M	―	-57.83%	―	―	―

Hookipa Pharma Corporate Events

Hookipa Pharma Approves Asset Sale and Liquidation

On July 29, 2025, HOOKIPA Pharma Inc. held a special meeting of stockholders where they voted on several significant proposals. The stockholders approved the sale of certain assets to Gilead Sciences, Inc., the liquidation and dissolution of the company, and the potential adjournment of the meeting to solicit additional proxies if needed.

Hookipa Pharma to Delist from Nasdaq Amid Asset Sale

On July 18, 2025, HOOKIPA Pharma Inc. announced its intention to voluntarily delist its common stock from the Nasdaq Capital Market and deregister under the Securities Exchange Act of 1934. This decision follows an asset purchase agreement with Gilead Sciences, Inc., where Gilead will acquire assets related to HOOKIPA’s HB-400 and HB-500 programs. The delisting and deregistration are part of HOOKIPA’s strategic plan to dissolve and liquidate, pending stockholder approval at a special meeting on July 29, 2025. The move is aimed at reducing compliance costs and maximizing asset distribution to stockholders.